Prelude Therapeutics Incorporated (PRLD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Prelude Therapeutics (PRLD) carries a +9.72% Earnings ESP into its Q3 2026 report, a positive reading that points to an earnings beat. The stock also holds a Zacks Rank #2.

Consensus calls for a quarterly loss of $0.14 per share, a 46.2% year-over-year improvement. Revenue is projected at $5 million, down 23.1% from the year-ago period. The widening gap between a shrinking loss and falling sales is the key tension in the setup.

A positive ESP means the most recent analyst estimates sit above the broader consensus figure, which the Zacks framework reads as a signal that the company is likely to top the Street. PRLD's track record supports that read: it has beaten consensus estimates in each of the last four quarters.

Interpretation: the improving per-share loss alongside declining revenue suggests the narrower loss may stem from cost dynamics rather than top-line growth, though the source does not break out the drivers. A beat on the loss line would extend the four-quarter streak, but the 23.1% revenue decline remains a soft spot that could limit enthusiasm.